Young Adults and Colorectal Cancer: A Growing Mystery

She was thirty-two and fit. Then came the diagnosis: colorectal cancer. The surprise in that single sentence captures why epidemiologists are unsettled. For decades, most cancer curves have dipped or flattened, and deaths from many cancers have fallen even as populations age. Yet one odd wrinkle has emerged — more people under fifty are being diagnosed with colorectal cancer, and nobody has a neat explanation.

Colorectal cancer, which covers cancers of the colon and rectum, is still far more common in older adults. Overall incidence and mortality have largely declined thanks to screening, better treatments, and prevention. But look at the under-50 group and a different picture appears: a slow but persistent rise in cases that started decades ago and continues in many places today. Strange. Troubling. Hard to pin down.

Where do explanations fall short? Some point to agricultural chemicals like picloram. Others blame PFAS, the so-called forever chemicals. These substances have been linked to health risks in lab and observational studies. But exposure patterns don’t line up with the disease pattern. Many of these chemicals were used more widely in the 1980s and 1990s, meaning older generations would typically have had higher lifetime exposure. If that were the main driver, we would expect older people to show the rise, not younger ones.

Obesity is a more plausible suspect. Weight gain is a known risk factor for colorectal cancer, and younger cohorts today are, on average, heavier than their counterparts decades ago. Yet obesity alone cannot explain the full puzzle. Modeling studies suggest weight gain may account for at best a modest portion of the excess risk — perhaps around 15 percent or less. Older adults have also become heavier over time, so obesity cannot neatly explain a trend that climbs among the young while at times leveling or falling among the old.

Geography adds another layer of confusion. The rise in early-onset colorectal cancer is not universal. Some countries, and even some regions within countries, show increasing rates in younger groups, while others have stable or falling rates. A multinational study from 2019 found that nearly half of analyzed countries did not experience an increase in young-onset disease. A follow-up analysis in 2025 painted a similarly fragmented picture. How could a single environmental toxin or lifestyle shift produce such disparate patterns across the globe?

Could changes in testing and diagnosis be part of the story? Screening guidelines have shifted only recently to include younger age groups, and the rise predates most of those changes. Still, healthcare is not static. Young people today may seek care differently, clinicians may be more likely to investigate symptoms that once were dismissed, and cancer registries have improved their capture of cases. Better detection could inflate measured rates even if the true underlying incidence is stable. But even this theory struggles to explain why older adults show different trends.

In short, the evidence points to a complex mix of influences rather than a single smoking gun. Multiple modest drivers — shifts in diet and gut microbiomes, changing patterns of antibiotic use, rising obesity, evolving diagnostic behavior, and patchy environmental exposures — could be combining in ways that vary by place and time. Think of it as a mosaic: no single tile tells the whole story; the pattern emerges only when you step back.

The rise in early-onset colorectal cancer remains largely unexplained, and that uncertainty is itself a call to action for better data and focused research.

Clinicians and public-health officials face a practical dilemma. Should screening age thresholds be lowered broadly? Should physicians test younger symptomatic patients more aggressively? Those decisions will need to balance limited resources, potential harms from overtesting, and the benefits of catching cancers early. Meanwhile, researchers are racing to untangle the drivers: finer-grained exposure histories, improved registries, and international comparisons that account for healthcare differences may finally illuminate why a cancer once considered a disease of later life is showing up younger and younger in some places.

We may not have the answer today, but the question is no longer academic — it has real consequences for patients, doctors, and public health systems worldwide.